Incidence and consequences of neonatal alloimmune thrombocytopenia: A systematic review

Pediatrics

Volumn 133, Issue 4, 2014, Pages 715-721

  Kamphuis, Marije M ^a   Paridaans, Noortje P ^a   Porcelijn, Leendert ^b   Lopriore, Enrico ^a   Oepkes, Dick ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

Author keywords

Intracranial hemorrhage; Neonatal alloimmune thrombocytopenia; Neonate; Screening

Indexed keywords

BLEEDING; BRAIN HEMORRHAGE; CONSENSUS; HEALTH CARE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEWBORN; PRENATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTE COUNT;

INTRACRANIAL HEMORRHAGE; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEONATE; SCREENING;

HUMANS; INCIDENCE; INFANT, NEWBORN; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84898714990     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-3320     Document Type: Review

References (22)

1. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G; Immune Thrombocytopenia Working Group. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood. 1997; 89(12):4402-4406
2. de Moerloose P, Boehlen F, Extermann P, Hohfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay. Br J Haematol. 1998;100(4):735-740
3. Murphy MF, Williamson LM. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK National Screening Committee. Br J Haematol. 2000;111(3):726-732
4. Risson DC, Davies MW, Williams BA. Review of neonatal alloimmune thrombocytopenia. J Paediatr Child Health. 2012;48(9):816-822
5. Kamphuis MM, Paridaans N, Porcelijn L, et al. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. BJOG. 2010;117(11):1335-1343
6. Kjeldsen-Kragh J, Killie MK, Tomter G, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839
7. Husebekk A, Killie MK, Kjeldsen-Kragh J, Skogen B. Is it time to implement HPA-1 screening in pregnancy? Curr Opin Hematol. 2009;16(6):497-502
8. Burrows RF, Kelton JG. Fetal thrombocytopenia and its relation to maternal thrombocytopenia. N Engl J Med. 1993;329(20):1463-1466
9. Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol. 1995;90(3):655-660
10. Sainio S, Järvenpää AL, Renlund M, Riikonen S, Teramo K, Kekomäki R. Thrombocytopenia in term infants: a population-based study. Obstet Gynecol. 2000;95(3):441-446
11. Uhrynowska M, Niznikowska-Marks M, Zupa-nska B. Neonatal and maternal thrombocytopenia: incidence and immune background. Eur J Haematol. 2000;64(1):42-46
12. Tiller H, Killie MK, Husebekk A, et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand. 2012;91(1):79-86
13. Castro V, Kroll H, Origa AF, et al. A prospective study on the prevalence and risk factors for neonatal thrombocytopenia and platelet alloimmunization among 9332 unselected Brazilian newborns. Transfusion. 2007;47(1):59-66
14. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? Vox Sang. 2003;84(4):318-325
15. Tiller H, Killie MK, Skogen B, Øian P, Husebekk A. Neonatal alloimmune thrombocytopenia in Norway: poor detection rate with nonscreening versus a general screening programme. BJOG. 2009;116(4):594-598
16. Madani K, Kamphuis MM, Lopriore E, Porcelijn L, Oepkes D. Delayed diagnosis of fetal and neonatal alloimmune thrombocytopenia: a cause of perinatal mortality and morbidity. BJOG. 2012;119(13):1612-1616
17. van den Akker ESA, Oepkes D, Lopriore E, Brand A, Kanhai HH. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective. BJOG. 2007;114(4):469-473
18. Spencer JA, Burrows RF. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol. 2001;41(1):45-55
19. Tiller H, Kamphuis MM, Flodmark O, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013;3(3): 3:e002490
20. Matsubara K, Nigami H, Yura K, Inoue T, Isome K, Fukaya T. Serum thrombopoietin level and thrombocytopenia during the neonatal period in infants with Down's syndrome. J Perinatol. 2010;30(2):98-102
21. Turner ML, Bessos H, Fagge T, et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion. 2005;45(12):1945-1956
22. Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Costeffectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG. 2007;114(5):588-595